Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Accumulated Expenses (2016 - 2025)

Arcadia Biosciences' Accumulated Expenses history spans 12 years, with the latest figure at $107000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2040.0% year-over-year to $107000.0; the TTM value through Dec 2025 reached $107000.0, up 2040.0%, while the annual FY2025 figure was $107000.0, 2040.0% up from the prior year.
  • Accumulated Expenses reached $107000.0 in Q4 2025 per RKDA's latest filing, up from $5000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $107000.0 in Q4 2025 to a low of $4000.0 in Q4 2023.
  • Average Accumulated Expenses over 5 years is $34600.0, with a median of $6000.0 recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: plummeted 96.57% in 2021, then soared 2040.0% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $51000.0 in 2021, then plummeted by 88.24% to $6000.0 in 2022, then tumbled by 33.33% to $4000.0 in 2023, then increased by 25.0% to $5000.0 in 2024, then skyrocketed by 2040.0% to $107000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Accumulated Expenses are $107000.0 (Q4 2025), $5000.0 (Q4 2024), and $4000.0 (Q4 2023).